Vericel logo

VCEL - Vericel Share Price

$43.63 2.4  5.8%

Last Trade - 25/01/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.37bn
Enterprise Value £1.31bn
Revenue £86.5m
Position in Universe 2152nd / 6623
Bullish
Bearish
Unlock VCEL Revenue
Momentum
Relative Strength (%)
1m +37.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -0.19%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
137.4
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
28.8 51.2 54.4 63.9 90.9 117.9 123.8 157 +32.6%
+4,900
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, VericelCorp revenues increased 1% to $79M. Net loss decreased 51%to $9.4M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Lower net loss reflects Research anddevelopment - other decrease of 66% to $8.4M (expense),Stock-based Compensation in R&D decrease of 27% to $1.5M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VCEL Revenue Unlock VCEL Revenue

Net Income

VCEL Net Income Unlock VCEL Revenue

Normalised EPS

VCEL Normalised EPS Unlock VCEL Revenue

PE Ratio Range

VCEL PE Ratio Range Unlock VCEL Revenue

Dividend Yield Range

VCEL Dividend Yield Range Unlock VCEL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VCEL EPS Forecasts Unlock VCEL Revenue
Profile Summary

Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.. Its autologous cell therapy products include Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated March 24, 1989
Public Since February 4, 1997
No. of Shareholders: 165
No. of Employees: 241
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 45,428,794
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VCEL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VCEL
Upcoming Events for VCEL
Thursday 29th April, 2021 Estimate
Vericel Corp Annual Shareholders Meeting
Frequently Asked Questions for Vericel
What is the Vericel share price?

As of 25/01/21, shares in Vericel are trading at $43.63, giving the company a market capitalisation of £1.37bn. This share price information is delayed by 15 minutes.

How has the Vericel share price performed this year?

Shares in Vericel are currently trading at $43.63 and the price has moved by 0.146k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vericel price has moved by 0.111k% over the past year.

What are the analyst and broker recommendations for Vericel?

Of the analysts with advisory recommendations for Vericel, there are there are currently 4 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Vericel is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Vericel next release its financial results?

Vericel is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Vericel dividend yield?

Vericel does not currently pay a dividend.

Does Vericel pay a dividend?

Vericel does not currently pay a dividend.

When does Vericel next pay dividends?

Vericel does not currently pay a dividend.

How do I buy Vericel shares?

To buy shares in Vericel you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vericel?

Shares in Vericel are currently trading at $43.63, giving the company a market capitalisation of £1.37bn.

Where are Vericel shares listed? Where are Vericel shares listed?

Here are the trading details for Vericel:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: VCEL
What kind of share is Vericel?

Based on an overall assessment of its quality, value and momentum, Vericel is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vericel share price forecast 2021?

Shares in Vericel are currently priced at $43.63. At that level they are trading at 0.15% premium to the analyst consensus target price of 0.00.

Analysts covering Vericel currently have a consensus Earnings Per Share (EPS) forecast of 0.006 for the next financial year.

How can I tell whether the Vericel share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vericel. Over the past six months, the relative strength of its shares against the market has been 0.121k%. At the current price of $43.63, shares in Vericel are trading at 0.111k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vericel PE Ratio?

The Vericel PE ratio based on its reported earnings over the past 12 months is 58.9k. The shares are currently trading at $43.63.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Vericel?

Vericel's management team is headed by:

Alan Rubino - IND
Robert Zerbe - CHM
Dominick Colangelo - PRE
Heidi Hagen - IND
Steven Gilman - IND
Kevin McLaughlin - IND
Paul Wotton - IND
Michael Halpin - COO
Sandra Pennell - CFO
Who are the major shareholders of Vericel?

Here are the top five shareholders of Vericel based on the size of their shareholding:

Brown Capital Management, LLC Investment Advisor
Percentage owned: 8.61% (3.91m shares)
RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 8.48% (3.85m shares)
Ivy Investment Management Company Investment Advisor
Percentage owned: 6.11% (2.77m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6% (2.73m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.08% (2.31m shares)
Similar to VCEL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.